Autosomal Dominant Polycystic Kidney Disease Pipeline — VivoSeq

Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Recruiting·JJemincare·Phase 2·NCT06800651·135 enrolled

Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease

Recruiting·—·Phase 2·NCT06435858·40 enrolled

A Phase I Randomised, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD1613 Following Multiple Ascending Dose Administration in Participants With Autosomal Dominant Polycystic Kidney Disease

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT07228364·40 enrolled

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Recruiting· AbbVie logo

AbbVie·Phase 2·NCT06902558·240 enrolled

A Pilot Study for Managing Depressive Symptoms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Recruiting·MMayo Clinic·Preclinical·NCT07745920·105 enrolled

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenously Administered PYC-003, a Peptide-phosphorodiamidate Morpholino Oligonucleotide Conjugate, in Healthy Adult Participants and Adult Participants With Confirmed PKD1 Mutation-associated Autosomal Dominant Polycystic Kidney Disease

Recruiting·PPYC Therapeutics·Phase 1·NCT06714006·166 enrolled

Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease

Active, not recruiting·UUniversity of Colorado, Denver·Phase 2·NCT05510115·50 enrolled

Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)

Active, not recruiting·HHannover Medical School·Phase 4·NCT06391450·44 enrolled

A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants

Active, not recruiting· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 2·NCT07161037·26 enrolled

A Study to Determine the Prevalence and Clinical Characteristics Associated With PKD1 Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Active, not recruiting· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·N/A·NCT06747572·401 enrolled

Safety of RotigotiNe in Patients With Autosomal Dominant Polycystic Kidney Disease

Not yet recruiting·UUniversity Hospital, Rouen·Phase 2·NCT06291116·120 enrolled

A Phase 1, Open-label Drug Interaction Study to Evaluate the Effect of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives

Not yet recruiting· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 1·NCT07792408·148 enrolled

Open Labeled , Randomized, Controlled, Crossover Trial on the Effect of a Carbohydrate Restricted Plant Dominant Diet on MCP-1 Mediated Inflammatory Signaling in Autosomal Dominant Polycystic Kidney Disease

Not yet recruiting·AAssaf-Harofeh Medical Center·Preclinical·NCT07651397·36 enrolled

Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease

Enrolling by invitation·TTaipei Medical University Shuang Ho Hospital·Phase 2·NCT05870007·30 enrolled

Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Completed· Otsuka logo

Otsuka·Phase 2·NCT01336972·29 enrolled

Autosomal Dominant Polycystic Kidney Disease

Pipeline Metrics

Competitive Landscape

Top Companies

Programs by Phase

Trial Status

Trial Activity